|Titre :||Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers (2010)|
|Auteurs :||K. H. LEVIN ; M. L. COPERSINO ; S. J. HEISHMAN ; F. LIU ; D. L. KELLY ; D. L. BOGGS ; D. A. GORELICK|
|Type de document :||Article : Périodique|
|Dans :||Drug and Alcohol Dependence (Vol.111, n°1-2, September 2010)|
|Article en page(s) :||120-127|
Thésaurus TOXIBASECANNABIS ; SYNDROME DE SEVRAGE ; ADULTE ; RECHUTE ; TOLERANCE ; SEVRAGE
Background: Cannabis withdrawal is not recognized in DSM-IV because of doubts about its clinical significance.
Objectives: Assess the phenomenon of cannabis withdrawal and its relationship to relapse in non-treatment-seeking adults.
Subjects: Convenience sample of 469 adult cannabis smokers who had made a quit attempt while not in a controlled environment.
Methods: Subjects completed a 176-item Marijuana Quit Questionnaire collecting information on sociodemographic characteristics, cannabis use history, and their "most difficult" cannabis quit attempt.
Results: 42.4% of subjects had experienced a lifetime withdrawal syndrome, of whom 70.4% reported using cannabis in response to withdrawal. During the index quit attempt, 95.5% of subjects reported >=1 individual withdrawal symptom (mean [SD] 9.5 [6.1], median 9.0); 43.1% reported >=10. Number of withdrawal symptoms was significantly associated with greater frequency and amount of cannabis use, but symptoms occurred even in those using less than weekly. Symptoms were usually of >= moderate intensity and often prompted actions to relieve them. Alcohol (41.5%) and tobacco (48.2%) were used more often than cannabis (33.3%) for this purpose. There was little change during withdrawal in use of other legal or illegal substances.
Conclusions: Cannabis withdrawal is a common syndrome among adults not seeking treatment. The intention to relieve withdrawal symptoms can drive relapse during quit attempts, giving cannabis withdrawal clinical significance as a target of treatment.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||Intramural Research Program, National Institute on Drug Abuse, 251 Bayview Blvd., Baltimore, MD 21224, USA|